Natixis Joins Eurex Clearing Ahead of EMIR Roll-Out

Nataxis has become a member of Eurex Securities Lending Central Counterparty (CCP) and EurexOTC Clear.

natixis
With Natixis, the Lending CCP now counts six clearing members while EurexOTC Clear has more than 40.

Part of Deutsche Börse Group, the clearing house will support the French institution in realizing benefits through operational and capital efficiencies. The integrated cross product clearing service will also allow for better collateral efficiency across securities lending, repo and derivatives. 

"The CCP model for Natixis will not only help manage the rising burden of balance sheet regulation and costs, we believe it will also prompt new stock-lending structures and business opportunities with non-standard profile counterparties," says Gregoire Froehlich, trader in securities lending and borrowing at Natixis.

"Going live with EurexOTC Clear is a key milestone in our strategy of offering our clients a large choice of CCPs ahead of the EMIR mandatory clearing roll-out," says Nicolas Chauvet, head of derivatives, treasury and forex operations at Natixis. "We are delighted that capital efficiency, cross margining and collateral management mechanisms proposed by EurexClearing are now available to both Natixis and its clients."

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: http://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Waters Wrap: The tough climb for startups

Anthony speaks with two seasoned technologists to better understand why startups have such a tough time getting banks and asset managers to sign on the dotted line.

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here